INTRODUCTION
Hematopoietic stem cell transplantation (HSCT) is a wellestablished therapeutic intervention for various congenital and acquired disorders of the hematopoietic system including a wide range of malignant and non-malignant disorders. 1 More than five decades have passed since the first report on the use of HSCT in children, and since that time there has been considerable progress and success of HSCT in a large variety of pediatric conditions as a result of better supportive care, refined conditioning regimens and expansion of donor stem cell sources. [2] [3] [4] Most published reports have analyzed data obtained through combined information on both adult and pediatric patients. There are only a few large-scale studies that described the HSCT activities and strategies used in children. [5] [6] [7] [8] [9] [10] [11] Most of these published studies described the status and outcome of HSCT in developed countries and were based on data collected through regional and international registries such as: Center for However, reports from developing countries, particularly the Eastern Mediterranean (EM) WHO region countries, have remained scant. The younger median age of HSCT recipients, predominance of inherited diseases, relative paucity of resources and experience, and variable socioeconomic challenges are unique to this part of the world.
The Eastern Mediterranean Bone Marrow Transplantation Group (EMBMT) was established in 2007 after a number of meetings between transplant teams from the EM region, with the aim of sharing experience, initiation of collaborative trials and the establishment of common strategies for transplantation, taking into consideration the specific issues and peculiarities relevant to the region. [12] [13] [14] The EMBMT pediatric cancer working committee was established in 2009. In this study we report on HSCT activities for children in the EM region. 1 
MATERIALS AND METHODS

Data collection
The data on HSCTs for pediatric patients (less than 18 years of age at the time of transplant) performed between 1984 and 2011 in eight EM region countries (Egypt, Iran, Jordan, Lebanon, Oman, Pakistan, Saudi Arabia and Tunisia) were collected using allogeneic and autologous transplant survey sheets. The data collected were as follows: primary disease categories, indication of transplant, donor type, stem cell source, intensity of conditioning regimen (myeloablative versus reduced intensity) as previously defined 15 and year of transplantation. The corresponding author and the central EMBMT office contacted the major transplant centers in each country reporting to EMBMT. The survey sheets were sent to programs with consistent annual performance of ⩾ 5 cases per year for at least 3 years. Data were then collected and analyzed. The information regarding population and gross national income per capita was obtained from WHO-EMRO office website (http://www.who.int/about/regions/ emro/en/index.html).
HSCT team density was calculated as the number of HSCT teams per 10 million population in each country. 14 The HSCT rate per 10 million population was also calculated. The list of the participating centers is shown in the Appendix.
Statistical analysis
Descriptive statistics was performed on demographic data showing counts and percentages for categorical data. A significance criterion of P o0.05 was used in the analysis. Analysis was performed using SAS version 9.1 (SAS Institute Inc., Cary, NC, USA).
RESULTS
Number of transplants
A total of 5187 transplants were performed between 1984 and 2011, of which 4513 were allogeneic (87%) and 674 were autologous (13%). The number of participating transplant teams, the availability of pediatric BMT program in each country, the reported numbers of HSCTs, team density, number of HSCT per 10 million populations and information on population are shown in Table 1 .
Saudi Arabia was the first country to perform HSCT (1984), followed by Lebanon (1988) , Iran (1991), Oman (1995), Egypt (1997), Tunisia (1998), Pakistan (2001) and Jordan (2003) . The largest number of transplants were performed in Saudi Arabia, with a total of 1977 transplants (38.2%), followed by Iran (n = 1197, 23.1%), Egypt (n = 811, 15.6%), Jordan (n = 361, 7%), Pakistan (n = 325, 6.2%), Tunisia (n = 249, 4.8%), Oman (n = 162, 3.1%) and Lebanon (n = 105, 2%). The highest rate of pediatric HSCT per 10 million population was reported in Saudi Arabia (820. 
Team density
The gross national income per capita-based WHO income in the EM region is shown in Table 1 . Most of the countries with pediatric transplant services are in the upper middle-income category, except Saudi Arabia and Oman, which are in the high-income group and Pakistan in the lower middle-income category. It is evident that there is a low-HSCT team density in most of the EM region countries. Moreover, many of high-income countries in the EM region are lacking pediatric HSCT services.
Indication for HSCT Allogeneic HSCT. Overall, there was a significantly higher number of transplants performed for patients with non-malignant diseases (n = 2777, 61.5%) compared with malignant diseases (n = 1736, 38.5%). However, for specific disease category indication, leukemia was the main disease indication for allogeneic HSCT (n = 1690, 37.5%), followed by hemoglobinopathies (n = 1081, 24%), bone marrow failure (BMF; n = 952, 21%), primary immunodeficiency (PID; n = 599, 13.3%), inherited metabolic disease (n = 132, 2.9%), lymphoma (n = 44, 1%) and solid tumor (n = 2; Figure 1a ).
Among patients with leukemia, AML in first CR was more common (n = 492, 29.1%), followed by ALL beyond CR1 (n = 354, 21%), ALL CR1 (n = 328, 19.4%), AML beyond CR1 (n = 191, 11.3%), CML in the first chronic phase (CP1; n = 158, 9.4%), myelodysplastic syndrome (MDS; n = 78, 4.6%) and myeloproliferative disorders, including juvenile myelomonocytic leukemia (n = 75,4.4%) and CML beyond CP1 (n = 14, 0.8%). Forty-four patients received allogeneic HSCT for lymphoma, mainly non-Hodgkin's lymphoma (NHL, n = 31), and only two patients received allogeneic HSCT for solid tumors (neuroblastoma and Ewing sarcoma).
For the non-malignant disorders, hemoglobinopathy was the most common indication (n = 1081, 39%), mainly thalassemia (n = 1033, 95.6%) followed by sickle cell disease (n = 32, 4.4%). The second most common indication was BMF (n = 952, 34.3%), mainly idiopathic aplastic anemia (n = 593, 62.3%), followed by Fanconi anemia (n = 294, 30.9%) and other hereditary BMF disorders (n = 61, 6.8%). The third most common indication was PID (n = 599, 21.6%), SCID(n = 221), followed by undefined PID (n = 214), hemophagocytic lymphohistiocytosis-related disorder (n = 93), leukocyte adhesion defect (n = 44) and Wiskott-Aldrich syndrome (n = 27). The fourth indication was inherited metabolic diseases (n = 132, 4.8%), including 55 transplants for osteopetrosis.
Autologous HSCT. A total of 674 patients underwent autologous HSCT, with lymphoma being the main indication with 291 transplants (43.2%), followed by other solid tumors (n = 248, 36.8%) and leukemia (n = 134, 19.9%; Figure 1b) .
Conditioning regimens A total of 3972 patients (88%) received conventional myeloablative conditioning and 471 (10.5%) received reduced-intensity conditioning (RIC), whereas 70 patients with PID (1.5%) received no conditioning. There was significant increase in the use of RIC in the last decade (Figure 2 ). 
DISCUSSION
This is the first report to describe HSCT activities for children in the EM region. The history of pediatric HSCT in the EM countries started in 1984 with matched related HSCT for a child with aplastic anemia (AA). This report analyzed data on 5187 transplants performed over almost three decades. Between 1985 and 2011, significant progress was made in the field of pediatric HSCT in the EM region. There was a significant increase in the number of HSCTs performed for malignant and non-malignant diseases, with some differences in donor selection and disease indications among countries.
The pediatric population constitutes~20% of the entire population in the western countries. However, in most of the EM and developing countries children represent much higher proportion of the population. 11 In addition, higher consanguinity rates and inter-related marriages lead to higher prevalence of genetic disorders, such as the hemoglobinopathies, PID, BMF and other hereditary disorders that can be cured with HSCT.
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Not all EM countries have comprehensive medical services to manage children with various malignant and non-malignant disorders. Accordingly, the group of patients who are in need for HSCT is heterogeneous and they often suffer from significant comorbidities upon referral to transplant services.
In several EM region countries, few or no HSCT services are available because of limited financial resources, lack of experienced medical team and inadequate governmental support. 13 The majority of allogeneic transplants in the EM region are from matched related donors. This is not surprising as approximately two-thirds of children who need HSCT can find suitable sibling and other related HLA-matched donors [16] [17] [18] [19] as a result of large families and the higher rate of consanguineous marriages. 20 It is much higher than the reported likelihood of finding matched related donors in western countries. 21, 22 It is expected that the need of HSCT for children with various malignant and nonmalignant diseases will continue to increase in the future. Healthcare providers in the EM region will face this important demand, and they should initiate real actions to establish pediatric HSCT services. In addition, there is a growing need to establish HSCT databases and registries in the EM region, which will help in identifying the trend and outcome of HSCT. 23 The pediatric HSCT team density is low in most of the EM countries, and is still lower than other countries and regions (such as Europe). 24 The number of transplants performed for non-malignant disorders in the EM region is higher than that for malignant diseases, which is opposite to what is reported in western countries. 24 The most common indication for HSCT in patients with nonmalignant disorders in the EM region was thalassemia major. The survival and quality of life of patients with thalassemia major with supportive therapy in developed countries is much superior than those living in developing countries. [25] [26] [27] [28] HSCT from HLA-matched family donor has significantly improved the prognosis of patients with thalassemia major. There are growing reports about good outcomes of HSCT for patients with thalassemia in the EM countries. 26, 29, 30 A significant percentage of patients with thalassemia major in the EM region suffer from iron overload, and some of them acquired hepatitis B or C infection from blood transfusions. The use of RIC-HSCT in those patients seems to be promising. 26 We also have unique challenges in our area related to delay in the diagnosis and referral for HSCT for patients with PID, which can adversely affect the transplant outcomes. 31 Efforts to implement newborn screening might result in early diagnosis and referral to HSCT.
Data and practices of HSCT for children with BMF disorders in the EM region represent one of the largest experiences worldwide, 29, 32 and can be used as resources for more research and studies in the future. The EM region has a similar trend to western and eastern European countries with regard to an increase in the use of PBSC as the stem cell source for autologous HSCT. 8, 9 The use of PBSC as the stem cell source for matched related pediatric HSCT has grown over the last decade in the EM countries. This preference might have contributed to faster engraftment and shorter duration of hospitalization, and therefore is more convenient for donors and physicians. In addition, increasing use of PBSC with RIC for patients with non-malignant disorders might be a contributing factor. 26 The HSCT practice in the EM region countries is heterogenous, with 18% of the centers performing pediatric transplants only, 35% performing adult transplants only and 47% performing both adult and pediatric transplants. 12 This might be related to the growing transplant experience and paucity of specialized pediatric transplant teams in the EM countries.
There is consistency in many of the pretransplant assessment measures and supportive care practice in most of the adult and pediatric EMBMT teams. 12 In primary diseases, indication and type of HSCT are different between adult and pediatric transplant services.
Because of limited resources and high cost, the use of alternative donors is very limited in the EM region. In addition, the infrastructure needed for unrelated HSCT such as CB banks, donor registries and regulations for unrelated stem cell donations is still underdeveloped and sparely distributed in the EM countries.
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Developing haplo-identical transplant protocols using post-transplantation cyclophosphamide is likely to facilitate the performance of HSCT for patients with no related family donor.
In conclusion, this is the first report to describe the pediatric HSCT activities in EM counties. There is an increase in the number of HSCT for children in the past two decades. Non-malignant disorders are the main indications for allogeneic transplantation. Performance of alternate donor transplantation remains limited, and the majority of the procedures used CB as the alternate donor stem cell source. Building a regional unrelated registry and CB banks might improve donor availability. Efforts are underway to establish an outcome registry in the EM region.
